Search Results

Expands Latin America presence with strategic partnership with Mobil Saúde and builds on TempraMed’s recently granted Brazilian patent portfolio Highlights: TempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world’s largest markets for diabetes, GLP-1 therapies, and temperature-sensitive biologics1. Diabetes market alone reached USD $2.15 Billion in 2025 Partnership builds on TempraMed’s recently granted Brazilian patent protecting the VIVI Box™ platform Expands TempraMed’s commercialization footprint across Latin America following recent regional expansion initiatives

Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to trial-stage candidates in this space.

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting industry employment will increase 9.7% by 2030. It also noted reskilling needs for some roles, including scientists.

With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.

Parabilis Medicines is joining the parade of biotechs going public, sharing plans to raise as much as $476.4 million to help advance its lead cancer candidate into late-stage testing.